134 related articles for article (PubMed ID: 27487149)
1. Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth.
Korang-Yeboah M; Patel D; Morton D; Sharma P; Gorantla Y; Joshi J; Nagappan P; Pallaniappan R; Chaudhary J
Oncotarget; 2016 Oct; 7(42):68072-68085. PubMed ID: 27487149
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.
Carey JP; Asirvatham AJ; Galm O; Ghogomu TA; Chaudhary J
BMC Cancer; 2009 Jun; 9():173. PubMed ID: 19500415
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, -2 and -3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity.
Sharma P; Chinaranagari S; Chaudhary J
Biochimie; 2015 May; 112():139-50. PubMed ID: 25778840
[TBL] [Abstract][Full Text] [Related]
5. ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells.
Komaragiri SK; Bostanthirige DH; Morton DJ; Patel D; Joshi J; Upadhyay S; Chaudhary J
Biochem Biophys Res Commun; 2016 Sep; 478(1):60-66. PubMed ID: 27462022
[TBL] [Abstract][Full Text] [Related]
6. Id4 dependent acetylation restores mutant-p53 transcriptional activity.
Knowell AE; Patel D; Morton DJ; Sharma P; Glymph S; Chaudhary J
Mol Cancer; 2013 Dec; 12():161. PubMed ID: 24330748
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer.
Sharma P; Chinaranagari S; Patel D; Carey J; Chaudhary J
Cancer Med; 2012 Oct; 1(2):176-86. PubMed ID: 23342267
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
9. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer.
Patel D; Knowell AE; Korang-Yeboah M; Sharma P; Joshi J; Glymph S; Chinaranagari S; Nagappan P; Palaniappan R; Bowen NJ; Chaudhary J
Mol Endocrinol; 2014 Aug; 28(8):1239-53. PubMed ID: 24921661
[TBL] [Abstract][Full Text] [Related]
11. Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells.
Carey JP; Knowell AE; Chinaranagari S; Chaudhary J
Anticancer Res; 2013 Oct; 33(10):4271-8. PubMed ID: 24122992
[TBL] [Abstract][Full Text] [Related]
12. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells.
Asirvatham AJ; Schmidt MA; Chaudhary J
Prostate; 2006 Jun; 66(9):921-35. PubMed ID: 16541417
[TBL] [Abstract][Full Text] [Related]
13. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles.
Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B
Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076
[TBL] [Abstract][Full Text] [Related]
15. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
16. Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization.
Korang-Yeboah M; Gorantla Y; Paulos SA; Sharma P; Chaudhary J; Palaniappan R
Int J Nanomedicine; 2015; 10():4763-81. PubMed ID: 26251597
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.
Gao XZ; Zhao WG; Wang GN; Cui MY; Zhang YR; Li WC
Mol Med Rep; 2016 Feb; 13(2):1269-74. PubMed ID: 26648013
[TBL] [Abstract][Full Text] [Related]
18. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
19. Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A
Breast Cancer Res; 2020 Jun; 22(1):63. PubMed ID: 32527287
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Ogura T; Tanaka Y; Tamaki H; Harada M
Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
